OP Asset Management Ltd Makes New $2.20 Million Investment in Kura Oncology, Inc. $KURA

OP Asset Management Ltd acquired a new stake in Kura Oncology, Inc. (NASDAQ:KURA) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 270,807 shares of the company’s stock, valued at approximately $2,202,000. OP Asset Management Ltd owned 0.31% of Kura Oncology as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. IFP Advisors Inc raised its stake in Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after purchasing an additional 3,072 shares during the last quarter. Allworth Financial LP increased its holdings in shares of Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after purchasing an additional 1,553 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after purchasing an additional 3,769 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in shares of Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the period.

Wall Street Analyst Weigh In

KURA has been the subject of several research analyst reports. CLSA set a $24.00 target price on shares of Kura Oncology in a report on Thursday, June 4th. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, June 15th. Wells Fargo & Company set a $24.00 price objective on Kura Oncology in a report on Thursday, June 4th. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research note on Thursday, May 28th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $25.46.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This trade represents a 31.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.60% of the stock is owned by corporate insiders.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $10.90 on Monday. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $967.59 million, a price-to-earnings ratio of -3.25 and a beta of 0.36. Kura Oncology, Inc. has a twelve month low of $5.45 and a twelve month high of $12.49. The company has a 50-day simple moving average of $9.57 and a two-hundred day simple moving average of $9.19.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The firm had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. Analysts forecast that Kura Oncology, Inc. will post -3.45 EPS for the current year.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.